全文获取类型
收费全文 | 1639篇 |
免费 | 130篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 53篇 |
妇产科学 | 20篇 |
基础医学 | 187篇 |
口腔科学 | 36篇 |
临床医学 | 174篇 |
内科学 | 375篇 |
皮肤病学 | 80篇 |
神经病学 | 56篇 |
特种医学 | 274篇 |
外国民族医学 | 1篇 |
外科学 | 162篇 |
综合类 | 43篇 |
预防医学 | 104篇 |
眼科学 | 23篇 |
药学 | 101篇 |
1篇 | |
中国医学 | 8篇 |
肿瘤学 | 56篇 |
出版年
2018年 | 14篇 |
2017年 | 10篇 |
2016年 | 14篇 |
2015年 | 16篇 |
2014年 | 19篇 |
2013年 | 25篇 |
2012年 | 28篇 |
2011年 | 42篇 |
2010年 | 43篇 |
2009年 | 42篇 |
2008年 | 38篇 |
2007年 | 47篇 |
2006年 | 44篇 |
2005年 | 35篇 |
2004年 | 37篇 |
2003年 | 36篇 |
2002年 | 40篇 |
2001年 | 42篇 |
2000年 | 30篇 |
1999年 | 37篇 |
1998年 | 58篇 |
1997年 | 44篇 |
1996年 | 44篇 |
1995年 | 55篇 |
1994年 | 45篇 |
1993年 | 47篇 |
1992年 | 30篇 |
1991年 | 30篇 |
1990年 | 46篇 |
1989年 | 62篇 |
1988年 | 49篇 |
1987年 | 55篇 |
1986年 | 56篇 |
1985年 | 39篇 |
1984年 | 40篇 |
1983年 | 44篇 |
1982年 | 28篇 |
1981年 | 25篇 |
1980年 | 30篇 |
1979年 | 31篇 |
1978年 | 29篇 |
1977年 | 33篇 |
1976年 | 23篇 |
1975年 | 19篇 |
1974年 | 12篇 |
1973年 | 18篇 |
1972年 | 13篇 |
1971年 | 21篇 |
1970年 | 10篇 |
1968年 | 13篇 |
排序方式: 共有1772条查询结果,搜索用时 15 毫秒
1.
Stephen R. Thomas Ronald G. Pratt Ronald W. Millard R. C. Samaratunga Yoseph Shiferaw Leland C. Clark Richard E. Hoffmann 《Journal of magnetic resonance imaging : JMRI》1994,4(4):631-635
Oxygen-sensitive F-19 magnetic resonance imaging of perfluorocarbon compounds requires that fluorocarbon T1 changes correlate with the local Po2 and not with the composition of the surrounding aqueous phase. The influence of various bioconstituents and paramagnetic ions within the aqueous phase on the F-19 fluorocarbon phase T1 for PFC emulsions was evaluated at 0.14 and 0.66 T. T1 was measured for FC-43, perflubron, and a fluorinated surfactant. Controlled variables introduced in the aqueous phase included annex solution constituents, blood, pH changes, and Gd-DTPA. For a constant Po2, the F-19 T1s were independent of the emulsion constituents, blood concentration, and pH. For FC-43 and perflubron, F-19 T1 was independent of the Gd-DTPA concentration, while the aqueous phase T1 decreased by more than an order of magnitude. XMO-10 (smallest emulsion particle size) showed a slight decrease in F-19 T1 with increasing Gd-DTPA concentration at 0.66 T. 相似文献
2.
3.
Studies were conducted to determine the effects of a potent narcotic antagonist, nalmefene methyliodide, which does not cross the blood-brain barrier (BBB), on the secretion of anterior pituitary hormones and on the anterior pituitary hormonal response to morphine sulfate. Since the localization of opiate receptor responses to inside or outside the BBB depended upon the relative ability of nalmefene HCl and nalmefene methyliodide to penetrate the BBB, initial studies were conducted to document that nalmefene methyliodide does not block opiate receptors inside the central nervous system. While nalmefene HCl blocked morphine-induced antinociceptive responses at doses as low as 10 micrograms/kg, nalmefene methyliodide was ineffective in this regard at doses as high as 500 micrograms/kg. The luteinizing hormone (LH) suppression and prolactin (PRL) secretion induced by morphine was blocked by both nalmefene HCl and its methyliodide analogue, indicating that the opioid receptor type which mediates both responses is located outside the BBB. We observed that basal PRL levels were reduced by nalmefene HCl but not by nalmefene methyliodide indicating that basal PRL secretion is influenced by opioid neurons inside the BBB. While nalmefene HCl blocked morphine-induced suppression of thyroid-stimulating hormone (TSH) release, nalmefene methyliodide was less effective, suggesting that opiate-induced TSH suppression may be mediated by receptors located both within and outside the BBB. Nalmefene HCl caused a growth hormone (GH)-secretory response by itself, but nalmefene HCl and nalmefene methyliodide were ineffective in blocking morphine-induced GH secretion.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
4.
5.
RAFAEL BEYAR M.D. D.Sc. ARIEL ROGUIN M.D. JAAP HAMBURGER M.D. RE SAAIMAN M.D. ANTONIO L. BARTORELLI M.D. CARLO DiMARIO M.D. ANTONIO COLOMBO M.D. CHRISTIAN W. HAMM M.D. CHRISTOPHER J. WHITE M.D. J. MARCO M.D. PATRICK W. SERRUYS M.D. Ph.D. 《Journal of interventional cardiology》1997,10(4):277-286
The beStent is a new stainless steel, balloon-expandable mesh stent which has a unique serpentine design. Rotation of the unique low stress junctions upon expansion leads to orthogonal locking of the wires, maximizing radial strength and assuring zero shortening. The stent has delineating gold markers which assure precise positioning. We aim to present the initial acute results in a pilot registry for stent evaluation. Two hundred eighty-four stents were used in a total of 217 patients (age 57.9 ± 3.10 years; 178 males; 39 females) in seven centers, for variable indications. Stents of 15-, 25-, and 35-mm length were used. The arteries treated were the left anterior descending (n = 112, 42%), circumflex (n = 54, 20.2%), right coronary (n = 95, 35.5%), left main (n = 1, 0.4%), and vein graft (n = 5, 1.9%). Lesion types were: A in 42 patients (16.5%); B1 in 53 patients (20.7%); B2 in 81 patients (31.8%); and C in 79 patients (31%). One hundred fifty-nine patients required one stent, 40 patients required two stents, and 18 patients required three or more stents. Anticoagulation protocol included procedural heparin with aspirin with/without ticlopidine. Smooth angiographie results were obtained in all cases with no plaque herniation. Acute angiographic success was obtained in 97% of the patients, and acute clinical success in 95% of the patients. Complications within 30 days were: 3 deaths (1.4%) (2 noncardiac); 2 (0.9%) myocardial infarctions; and 2 (0.9%) stent thromboses. Therefore, the beStent is useful in treatment of complex lesions of variable length and complexity, providing excellent acute results with a low complication rate, in spite of unfavorable basic clinical and angiographie characteristics. 相似文献
6.
7.
Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results 总被引:3,自引:0,他引:3
Mattrey RF; Strich G; Shelton RE; Gosink BB; Leopold GR; Lee T; Forsythe J 《Radiology》1987,163(2):339-343
In animals, perfluorochemicals (PFCs) are effective ultrasound (US) contrast agents that produce hepatic, splenic, and tumor enhancement. The use of Fluosol-DA 20%, an emulsion of perfluorodecalin and perfluorotripropylamine, was studied in nine non-critically ill patients with cancer who had liver lesions. US studies without Fluosol were compared with studies obtained 24, 48, and 72 hours after Fluosol infusion. Vital signs and extensive laboratory analyses are performed before and after Fluosol infusion. Liver metastases from colonic, pancreatic, and gastric carcinoma exhibited rim or diffuse enhancement after a Fluosol dose of 1.6 g/kg or greater. Fluosol produced echogenic enhancement of the liver and spleen relative to kidney at a dose of 2.4 g/kg, allowing the detection of nonenhancing lesions. In addition, Fluosol at a dose of 1.6 g/kg or greater allowed detection of lesions not seen before contrast medium was administered in three of the seven patients studied. There was a mild increase in the level of serum glutamic oxaloacetic transaminase in two patients, one given 2.4 and the other 3.2 g/kg of Fluosol. Mild and transient allergic reactions without change in vital signs were experienced by two patients. 相似文献
8.
9.
10.
C J Gilleard J M Kellett J A Coles P H Millard M Honavar P L Lantos 《Acta psychiatrica Scandinavica》1992,85(4):264-269
Sixty-four elderly patients who had been admitted to the St. George's Hospital Alzheimer's disease evaluation project during 1981-1989 were followed up to postmortem examination. Comparison between clinical diagnoses and neuropathological diagnoses indicated positive predictive values for the antemortem diagnoses of 50-67%. Existing clinical criteria may not be accurate enough to permit firm antemortem diagnosis of older people for either research or clinical purposes. 相似文献